Press releases

Increased manufacturing capacity combined with an expansion from 69 to 92 eligible countries, is expected to enable delivery of more than 320 million doses through 2030 Previously guaranteed...

Continues Strong Performance and Progress Toward Achieving BD 2025 Strategy; Advances Innovation Pipeline and Receives Clearance for Updated BD Alaris™ Infusion System Revenue of $4.9 billion...

Single Test on BD MAX™ System Identifies and Differentiates Multiple Respiratory Infectious Diseases from One Sample FRANKLIN LAKES, N.J., Aug. 1, 2023 /PRNewswire/ -- BD (Becton, Dickinson and...

The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.91 per common share, payable on September 29, 2023 to holders of record on...

Reflects Commitment to Gender Equality and Progress in Advancing ESG Strategy FRANKLIN LAKES, N.J. (July 25, 2023) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Dr. Joanne Waldstreicher to its board of directors. Waldstreicher,...

BD (Becton, Dickinson and Company) (NYSE: BDX) Chairman, CEO and President Tom Polen issued the following message regarding the U.S. Food and Drug Administration (FDA) 510(k) clearance for the...

BD Alaris™ Infusion System is the only modular and most comprehensive infusion system on the U.S. market that includes large volume pumps, syringe pumps, patient-controlled analgesia (PCA)...

Company Expands its ESG Focus Areas to Include Advancing Health Equity in Under-Resourced Communities FRANKLIN LAKES, N.J., July 20, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:...

FRANKLIN LAKES, N.J. (July 13, 2023) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it is one of 200 companies named to U.S....